The group's principal activities are to discover, develop and market oncology products. The group's advanced drug tarceva(tm); an anti-cancer agent is undergoing phase iii clinical trials for non-small lung cancer and pancreatic cancer. Tarceva(tm) is being developed in a global alliance with genentech inc and roche holdings inc. In addition, it has five other drug candidates in early stages of clinical development, out of which three are next generation cytotoxic chemotherapy agents and three are gene-targeted therapies currently being developed by pfizer inc. The products of the group include novantrone(R) and gelclair(r). On, 12-Jun-2003, the group acquired cell pathways inc.
